


#4

PATENT
Docket No. 313632000801

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202, on April 18, 2002

Tami M. Procopio



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Ton LOGTENBERG and Cornelis
Andriaan DE KRUIF

Serial No.: 10/039,059

Filing Date: December 31, 2001

For: ALTERING THE PROPERTIES OF
CELLS OR OF PARTICLES WITH
MEMBRANES DERIVED FROM
CELLS BY MEANS OF
LIPID-MODIFIED PROTEINACEOUS
MOLECULES

Examiner: To be Assigned

Group Art Unit: To be Assigned

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This is in response to the Notice to file corrected application papers, dated February 19, 2002, for which a response is set to expire April 19, 2002. Accordingly, this response is timely filed.

Please enter the following Sequence Listing, amendments and remarks.

In the Sequence Listing:

Please insert the attached paper copy of the Sequence Listing as new page 1 in the above-captioned application. A computer-readable copy (CFR copy) of the Sequence Listing accompanies this response.

Amendments

In the Specification:

Please replace the paragraph beginning at page 20, line 22, with the following rewritten paragraph:

--Expression vector pLP2 was constructed by inserting a small hydrophilic linker (Pack, P. et al. 1993, Bio/technology, 11:1271-1277) into vector pLPscH (de Kruif et al. 1996, FEBS lett. 399:232-236), (figure 1a). The full-encoded sequence of the N-terminus of LT-scFv proteins expressed in vector pLP2 is:

MKATKLVLGAVILGSTLLAGCSSNAKIDQPKPSTPPGSSAMA (SEQ ID NO:1).--

REMARKS

The Specification has been amended to include sequence identifications numbers which were omitted at the time of filing.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "**Version with markings to show changes made.**".

The undersigned hereby states that the computer readable form copy (CRF copy) of the Sequence Listing and the paper copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. **313632000801**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: April 18, 2002

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

The paragraph beginning at page 20, line 22, has been amended as follows:

Expression vector pLP2 was constructed by inserting a small hydrophilic linker (Pack, P. et al. 1993, Bio/technology, 11:1271-1277) into vector pLPscH (de Kruif et al. 1996, FEBS lett. 399:232-236), (figure 1a). The full-encoded sequence of the N-terminus of LT-scFv proteins expressed in vector pLP2 is:

MKATKVLGAVILGSTLLAGCSSNAKIDQPKPSTPPGSSAMA (SEQ ID NO:1).